India's chemical corridor: $901M in organic compounds flow to Swiss labs

Swiss laboratories and precision manufacturing facilities are witnessing a major shift as India's pharmaceutical exports stood at USD 30.47 billion in 2024-25, registering a growth of 9.4 percent over the previous year, with organic chemical compound shipments now representing the single largest sector flowing between the world's 4th largest economy and Alpine markets.

Swiss Federal Customs data reveals organic chemicals worth $901.6 million crossed from India in 2025 — a remarkable emergence from virtually zero the previous year. This sector's meteoric rise positions it as India's dominant export category to Switzerland, outpacing all others including vegetables ($101.6 million) and animal products ($29.6 million). Under the terms of the agreement, EFTA states will eliminate or sharply reduce tariffs on the vast majority of imports from India, covering about 99.6% of India's export value to EFTA, creating unprecedented opportunities for Indian pharmaceutical manufacturers.

Complex Chemistry Powers Bilateral Trade

Within India's organic chemicals breakthrough, amino-naphthols and related compounds lead at $31.0 million, followed closely by cyclic amides at $26.1 million and unsaturated monocarboxylic acids at $25.3 million. These specialized intermediates form the backbone of pharmaceutical manufacturing, feeding directly into Switzerland's precision medicine and biotechnology sectors.

Sun Pharma, it appears, is the highest export-dependent company, with close to two-thirds of its revenues coming from exports to overseas markets, making TEPA's tariff eliminations particularly significant for India's largest pharmaceutical company by revenue. Leading the charge is Sun Pharma, which tops the list with remarkable net sales of ₹20,812.14 crore. Not far behind, Dr. Reddy's Labs and Cipla secure the second and third positions with revenues of ₹16,962.50 crore and ₹15,790.60 crore, respectively.

"The agreement is also advantageous for Indian exporters, particularly those in the organic chemicals, pharmaceuticals, and food processing industries, targeting the EFTA and Swiss markets."

Competition dynamics reveal India capturing 189% market share versus the traditional $123.0 million Swiss organic chemicals import market — indicating substantial market expansion rather than displacement. Germany remains the largest supplier at $40.5 million, but India's $22.7 million represents rapid acceleration from zero baseline.

Industrial Clusters Power Export Machine

India's pharmaceutical sector is led by five regions: Gujarat, Pune, Mumbai, Hyderabad, and Bengaluru, with each contributing distinct capabilities to the organic chemicals value chain. Mumbai is the pharmaceutical business capital focusing on generic medicines, APIs, and complex formulations; Ahmedabad is known for biotech manufacturing emphasizing generics, biosimilars, and vaccines, while Hyderabad, also referred to as the 'Vaccine Hub of India', is the absolute leader in Indian pharmaceutical innovation and knowledge-based industries, including biotechnology, pharmaceuticals, IT, and ITES. The city has many multinational life sciences giants like United States Pharmacopeia (USP), DuPont, Albany Molecular Research Inc. (AMRI), Nektar Therapeutics, Sanofi Aventis, Aptuit-Laurus and many more domestic industries such as Dr Reddy's, Aurobindo Pharma, Bharat Biotech and many more.

Hyderabad Pharma City (HPC): It is the world's largest pharmaceutical cluster, dedicated to research and manufacturing. Recognized as a National Investment and Manufacturing Zone (NIMZ) by the central government, it is located 25 kilometers from Shamshabad airport. Covering 19,000 acres, HPC employs over 560,000 professionals and offers a streamlined infrastructure, reducing setup times and costs. Expected to attract US$ 9.7 billion in investments, the cluster accelerates growth for life sciences companies and enhances Hyderabad's global pharmaceutical prominence.

Gujarat's Ahmedabad corridor demonstrates particular strength in complex organic synthesis, with one of India's most mature life sciences clusters, the Ahmedabad–Vadodara corridor integrates large-scale pharmaceutical manufacturing with an expanding biotech research ecosystem. Mumbai's precision continues driving API production, leveraging a highly skilled workforce, with talent from premier institutions like the Institute of Chemical Technology (ICT) and several regional medical colleges. The pharma ecosystem in Mumbai is further strengthened by the presence of healthcare providers, diagnostic centres, and clinical research organizations (CROs). The city plays a crucial role in India's position as a global supplier of generic medicines and APIs, ensuring timely delivery to international markets.

Employment Ripple Effects Across States

The $901.6 million organic chemicals sector directly supports an estimated 8,138 manufacturing jobs across India's pharmaceutical clusters, using pharmaceutical sector multipliers of 3.5 direct jobs per $100,000 in exports. Indirect employment through supply chains, logistics, and services generates an additional 20,925 positions, creating total employment impact of approximately 29,063 livelihoods.

Maharashtra leads employment generation through Mumbai's API manufacturing base, while Gujarat's Ahmedabad region contributes significantly through specialty chemical synthesis operations. As per the study findings, most (87.6%) units in pharma clusters are MSMEs. The study found that these MSMEs in pharma clusters form an essential part of the supply chain for the large industries, indicating broad-based participation in the Switzerland trade corridor.

Women's participation reaches an estimated 30% across the organic chemicals manufacturing chain, translating to approximately 8,719 women directly and indirectly employed in Switzerland-bound production. Telangana's Genome Valley particularly benefits, with more than 200 companies from 18 countries, employing around 25,000 people contributing to export operations.

The Hyderabad-Shamirpet biotechnology corridor alone houses contract research organizations producing Switzerland-destined compounds, while Mumbai's Thane-Aurangabad belt specializes in complex API synthesis feeding European pharmaceutical supply chains.

Forward Trajectory Under TEPA Framework

Participants were apprised of recent developments in India's international trade framework, including the India–UK Comprehensive Economic and Trade Agreement (CETA) signed on 24 July 2025, and the India–European Free Trade Association (EFTA) Trade and Economic Partnership Agreement (TEPA), which became effective on 1 October 2025. Emphasis was placed on the binding zero-tariff provisions in these agreements and their potential to enhance the competitiveness of Indian generic medicines, as well as the investment and employment opportunities arising from them.

The Commerce Secretary also highlighted that India's domestic pharmaceutical market is currently estimated at around USD 60 billion. Shri Agrawal said that the market is expected to double to approximately USD 130 billion by 2030, reflecting the sector's scale, depth, and innovation potential, providing strong domestic foundation for export expansion.

All Swiss pharmaceutical products will enjoy improved market access, with nearly all tariffs eliminated after transition periods. Swiss chemical products will benefit from either full tariff elimination or significant reductions, creating reciprocal opportunities as Indian organic chemicals gain preferential access to Swiss precision manufacturing supply chains.

The sector's trajectory benefits from The EFTA countries committing to invest 100 billion USD in India which is expected to lead to 1 million new jobs over the next 15 years, with significant portions targeting pharmaceutical and chemical manufacturing infrastructure expansion.

Data source: Swiss Federal Customs (SITC Rev.5), 2025. Employment estimates based on pharmaceutical sector multipliers: 3.5 direct jobs and 9.0 indirect jobs per $100,000 export value.